ARGENX SE EO -,10/ NL0010832176 /
| 2024-04-19 8:23:47 AM | Chg. -5.7000 | Volume | Bid8:03:30 PM | Ask8:03:30 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 333.6000EUR | -1.68% | 0 Turnover: 0.0000 |
332.5000Bid Size: 10 | 342.6000Ask Size: 10 | 19.98 bill.EUR | - | - |
GlobeNewswire
04-16
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire
03-27
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire
03-26
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire
03-07
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire
02-29
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire
02-22
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire
02-20
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...
GlobeNewswire
01-18
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...
GlobeNewswire
2023-12-07
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire
2023-11-28
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...
GlobeNewswire
2023-11-16
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...
GlobeNewswire
2023-11-13
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-11-09
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2023-11-07
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GlobeNewswire
2023-11-01
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
GlobeNewswire
2023-11-01
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...
GlobeNewswire
2023-10-31
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-10-24
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
GlobeNewswire
2023-10-18
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
